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ABSTRACT
Accurate variant calling in next generation sequenc-
ing (NGS) is critical to understand cancer genomes
better. Here we present VarDict, a novel and versa-
tile variant caller for both DNA- and RNA-sequencing
data. VarDict simultaneously calls SNV, MNV, InDels,
complex and structural variants, expanding the de-
tected genetic driver landscape of tumors. It per-
forms local realignments on the fly for more accu-
rate allele frequency estimation. VarDict performance
scales linearly to sequencing depth, enabling ultra-
deep sequencing used to explore tumor evolution or
detect tumor DNA circulating in blood. In addition,
VarDict performs amplicon aware variant calling for
polymerase chain reaction (PCR)-based targeted se-
quencing often used in diagnostic settings, and is
able to detect PCR artifacts. Finally, VarDict also de-
tects differences in somatic and loss of heterozygos-
ity variants between paired samples. VarDict repro-
cessing of The Cancer Genome Atlas (TCGA) Lung
Adenocarcinoma dataset called known driver muta-
tions in KRAS, EGFR, BRAF, PIK3CA and MET in
16% more patients than previously published variant
calls. We believe VarDict will greatly facilitate appli-
cation of NGS in clinical cancer research.
INTRODUCTION
Next-generation sequencing (NGS) has revolutionized our
understanding of genetic variants in cancer and their role
in cancer progression. As a platform for discovery NGS
has revealed new genetic drivers of cancer leading to devel-
opment of targeted cancer therapies (1), and in the clinic
NGS provides a tool to detect mutations determining a pa-
tient therapy (2). Cancer genomes are known to harbor a
wide range of mutations, including single nucleotide vari-
ants (SNVs), multiple-nucleotide variants (MNVs), inser-
tions, deletions and complex variants, in addition to even
more complex structural variants (SVs) such as duplications
(DUPs), inversions (INVs), insertions and translocations.
Oncogenes such as KRAS, NRAS, BRAF and EGFR, of-
ten contain hotspot missense mutations, which are the fo-
cus of most variant callers (3,4). A number of regularly
cited variant callers, such as GATK (3), FreeBayes (http:
//arxiv.org/abs/1207.3907) and VarScan (4) are designed to
call SNVand small InDels separately, but not complex com-
binations of these events. Furthermore tumor suppressors,
such as TP53, PTEN, BRCA1/2, RB1, STK11 and NF1,
often contain large frameshift insertions and deletions (In-
Dels) or complex mutations and sometimes even SVs (5)
and are often missed by those variant callers. To more com-
prehensively analyze cancer genomes, a variant caller that
can identify all these different types of mutations is needed.
In addition, ultra-deep sequencing (>5000×) is increas-
ingly applied in a clinical setting where low allele frequency
(AF) mutations are of key interest, for example to discover
mutations present in only a small sub-clonal proportion of
the tumor cells that might be resistant to targeted therapy
(6), or for detection of mutations in the often small pro-
portion of tumor DNA circulating with normal DNA in
a patient’s blood (7). Most commonly used variant callers
do not scale well with increasing depth and typically down-
sample (randomly remove portions of data) to increase their
computational performance. However downsampling can
significantly reduce the sensitivity to detect low AF mu-
tations. Coupled with its random nature, downsampling is
thus not desired in such situations. Variant callers that can
scale computational performance to comprehensively han-
dle ultra-deep sequencing data are urgently required to im-
prove sensitivity.
Here, we present a de novo and versatile variant caller,
VarDict, which can simultaneously call SNV, MNV, In-
Dels, complex composite variants, as well as SVs with no
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size limit. VarDict contains many features that are distinct
from other variant callers, including linear performance to
depth, intrinsic local realignment, built-in capability of de-
duplication, detection of polymerase chain reaction (PCR)
artifacts, accepting both DNA- and RNA-Seq, paired anal-
ysis to detect variant frequency shifts alongside somatic and
loss of heterozygosity (LOH) variant detection and SV call-
ing. We use a number of both simulated and real human
tumor sample whole-genome, exome and targeted sequenc-
ing data sets to compare VarDict to current gold standard
variant callers. VarDict demonstrates consistently improved
performance and sensitivity, particularly for InDels call-
ing. We believe VarDict will greatly facilitate application
of NGS in cancer research, enabling researchers to use one
tool in place of an alternative computationally expensive en-
semble of tools.
MATERIALS AND METHODS
Prerequisites
VarDict works on Binary Alignment/Map (BAM) files that
contain aligned sequence reads against a reference genome.
VarDict is compatible with BAM files generated from com-
mon DNA-Seq aligners, such as BWA (8), Novoalign (http:
//www.novocraft.com), Bowtie (9), andBowtie2 (10), as well
as RNA-Seq aligners, such as Tophat (11) and STAR (12).
Local realignments and InDel calling
VarDict performs two types of local realignments to more
accurately estimate allele frequencies for InDels: supervised
and unsupervised. InDels that are much shorter than the
read length and central to the reads are typically aligned
with gaps by most aligners, but result in forced alignment
with mismatches, or soft-clipping when mismatches are too
many. An example was shown in IGV (13) (Figure 1). This
mismatched and soft-clipped sequences are often ignored
or mis-treated by most variant callers, but in fact offer im-
portant additional evidence of the InDels. When such an
InDel is found in an alignment VarDict triggers supervised
local realignment to identify mismatched alignment of 3′
and 5′ read ends flanking the InDels and adds them in sup-
port of the InDel, resulting in increased allele frequencies.
In unsupervised local realignment, VarDict scans the local
sequences near soft-clippings to look for larger InDels. Var-
Dict first derives the consensus sequences from soft-clipped
reads clipped at the same genomic location. If a consensus
sequence can be found, VarDict then uses it to find an un-
gapped match within a user definable distance (default to
125 bp), but allowing ≤3 base mismatches. When a match
is found in entirety and away from the breakpoint, a dele-
tion is called; and when the end portion of the consensus
matches adjacent to the breakpoint, an insertion is called. If
no InDels can be called, VarDict identifies sequential well-
clipped sequences (typically within 5 bp) with respective 5′
and 3′ soft-clippings, assuming them to flank either side of
an insertion, and determines whether they have matched
ends. If an ungapped match is found with mismatches (≤3),
a large insertion is called. This approach enables calling of
insertions that are larger than read length, as well as large
complex variants.
Figure 1. VarDict uses soft-clipped reads for local realignment to compre-
hensively estimate allele frequency (AF). This example shows the 15-bp
deletion mutation in EGFR exon 19 in the PC-9 lung cancer cell line, as
shown in IGV. Top track is the coverage for each base pair. Each thin gray
line represents a sequence read. Black lines in the middle indicate gapped
alignments due to the 15-bp deletion. The colored portion shows soft-
clipped reads that cannot be aligned due to short overhangs. The bottom
track shows reference sequence and amino acids for EGFR exon 19.
Detecting complex variants
VarDict calls complex variants that are a combination of
insertions and deletions and typically off the limit or mis-
called by most currently published variant callers. We ob-
served that composite proximal (<10 bp) InDels and mis-
matches in the same reads typically work in tandem as one
complex variant. VarDict represents complex variant com-
posites as a single variant, rather than as multiple individ-
ual variants. Whenever an InDel is detected in a read, Var-
Dict will recursively scan for another InDel (within 10 bp)
or mismatches (within 3 bp) in the same read, and if found,
combines them as one variant. The same rule also applies
to consecutive mismatches, resulting in calling multiple nu-
cleotide variants (MNVs).
Structural variants
VarDict takes a two-step approach to call SVs. First it will
use soft-clipped reads as described above to build a con-
sensus sequence from clipped sequences, and then search
whether this consensus can be uniquely aligned within 5
kb of the given region. If a match is not found, VarDict
searches in the region suggested by discordant mate pair
alignment. In order to quickly find a match, VarDict builds
a hash table of all 17 and 11 bp seeds from reference se-
quences in the region, using only unique seeds to avoid
false positives. For even larger SVs where the second break-
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point is outside the given region, VarDict will use discor-
dant mates as a guide and search only in the regions sug-
gested by discordant mates to identify the other breakpoint
position. When the soft-clipped sequences can be uniquely
mapped, VarDict will call the SVs, perform a 5′ shift if nec-
essary and estimate theAF of the detected SV, a distinct fea-
ture from other published SV callers. When no soft-clipped
reads are found, VarDict will then use only clustered dis-
cordant mates to call SVs based on both distance and ori-
entation, and estimate the breakpoints as well as AF based
on number of discordant mates. Currently, VarDict imple-
ments large deletions (DEL), DUPs and INVs. Insertions
larger than two read lengths are not called, and will require
future development, including de novo assembly algorithms.
Also, inter-chromosome fusion (BND) calling has not yet
been implemented.
Paired analysis
In paired sample analysis mode, where two BAM files are
given, VarDict will extract the read counts for variant and
reference alleles and perform a Fisher’s exact test to deter-
mine whether a variant has a significant difference in AF
between the two samples. Based on the AF difference, a
variant is classified as ‘Somatic’ if only present in the first
sample, ‘Germline’ if present in both samples, ‘LOH’ if a
heterozygous variant in the second sample but becomes ho-
mozygous or is lost in the first sample, ‘Deleted’ if present
in the second sample but no coverage in the first sample.
Amplicon calling
When given PCR amplicon designs with primer locations,
VarDict will trigger ‘amplicon calling mode’. In this mode,
VarDict calls variants amplicon by amplicon. It first com-
pares the read mapping positions to the PCR design sup-
plied in a BED file with primer locations and determines
whether the read belongs to a particular PCR amplicon.
VarDict will then only use those read pairs that have 90%
overlap with the amplicon and fall within 10 bp of ampli-
con’s PCR edges, and avoids calling variants overlapping
the primers. Variants in regions covered by more than one
amplicon that cannot be called in all amplicons are consid-
ered amplicon biased and filtered out as PCR artifacts.
De-duplication
PCR duplicates in NGS are a predominant source of false
positives in variant calling. A typical NGS workflow in-
volves a separate de-duplication step to mark or remove
duplicates. VarDict has a built-in option to perform de-
duplication on the fly, removing the necessity for an addi-
tional step and so improving efficiency. Any read pairs with
the same alignment positions for both reads are deemed
duplicates and VarDict will only use the first one encoun-
tered for variant calling. VarDict also supports BAM files
where duplicates have already been marked and, by de-
fault, will exclude those reads marked as duplicates. The
de-duplication option is recommended for hybrid capture-
based sequencing, whole genome sequencing (WGS), and
perhaps RNA-Seq, but not for PCR-based targeted se-
quencing.
Memory management and run time
VarDict was designed to have efficient memory manage-
ment and run time for ultra-deep sequencing. VarDict con-
structs a unique data structure for the regions of interest,
such as exons, in memory to represent different types of
variants, thus making memory usage only proportional to
the region of interest, regardless of sequencing depth. It
parses reads mapped to the region sequentially and updates
the variant data structure accordingly. By generating a con-
sensus call for the set region to the most degenerative align-
ment, VarDict’s local realignment runs with computational
efficiency proportional to the sequencing depth, scaling lin-
early to depth. These combined features ensure VarDict is
uniquely suitable for computationally efficient and sensitive
variant calling from ultra-deep targeted sequencing, where
low allele frequencies are expected and downsampling is not
desired.
Data
Over the course of development, we used several datasets to
test VarDict as listed below:
(i) NA12878 and Genome In a Bottle (GIAB) vari-
ant calls: NA12878 WGS data was downloaded from
Platinum genome project (http://www.illumina.com/
platinumgenomes) and aligned using BWA (v0.7.8).
Version 17 of published GIAB calls (https://sites.
stanford.edu/abms/giab) were used for comparison to
VarDict calls.
(ii) ICGC-TCGA DREAM Mutation Calling challenge:
synthetic challenge 3 and 4. Each challenge was deeply
sequenced (60–80× coverage) WGS datasets from a
single (e.g. cell line) sample and then randomly sam-
pled into two non-overlapping subsets of equal size.
A non-overlapping spectrum of mutations was gen-
erated, some randomly selected and some targeting
known cancer-associated genes, whichwere then added
to one of the sampled BAM files which becomes the
‘tumor’, with the other being the ‘normal’.
(iii) The Cancer Genome Atlas (TCGA) lung dataset (14).
We downloaded exome BAM files of TCGA lung ade-
nocarcinoma (LUAD) from CGHub (https://cghub.
ucsc.edu/) for a given set of genes. BAM files were used
directly without re-alignment. VarDict was run with
de-duplication turned on (-t), requiring at least 4 sup-
porting reads (-r 4) withAF≥ 7.5% andminimumbase
quality ≥ 23 (-q 23) to call variants, but allowing allele
frequencies ≥ 2.5% for known mutations.
RESULTS
VarDict accurately estimates InDel allele frequency
The local realignment capability of VarDict enables accu-
rate estimation of AF for InDels. The local realignment
not only recovers unaligned terminal read portions that are
otherwise removed (‘soft-clipped’), but also terminal read
portions with short overhang that are otherwise forcefully
aligned with mismatches and can be miscalled as SNVs.
For a known EGFR exon 19 deletion in exome sequenc-
ing of cell line PC-9, we compared VarDict’s AF estimation
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to those from several other popular variant callers includ-
ing GATK (3), FreeBayes and VarScan (4). VarDict con-
sistently returned higher variant AF and depth indicating
more comprehensive consideration of all different support-
ing reads, as illustrated in Figure 1 and Table 1. The AF is
69% when only gap-opening reads are considered, as is the
case for GATK’s UnifiedGenotyper. VarDict recovers 26%
more reads from soft-clipped reads (shown as colors in Fig-
ure 1) from both sides of the deletion, as well as forced mis-
matches when overhangs are too short to be softly clipped
by the aligner. The GATKHaplotypeCaller and FreeBayes,
on the other hand, seem to only recover soft-clipped reads
from one side of the deletion, resulting in lower AF estima-
tions.
VarDict recovers large InDels from soft-clipped reads
Large InDel variants are often underrepresented, particu-
larly in cancer genomes, which have higher prevalence of
large InDels. One possible reason is large InDels are often
beyond the limits of detection by most variant callers or al-
lele frequencies are under-estimated. The unique local re-
alignment feature of VarDict makes it possible to call large
InDels (up to 125 bp by default, but can be user defined)
with sensitive AF estimation, even when supported by soft-
clipped reads alone. Figure 2 shows an example of a 124
bp deletion (rs67488720) from the human reference DNA
NA12878. VarDict not only correctly calls the deletion, as
supported by dbSNPand present in both parents (NA12891
at 100%,NA12892 at 44%), but also with estimated 56%AF
consistent with expectations for this heterozygous germline
variant. GATK-HaplotypeCaller (3), VarScan (4) and Free-
Bayes all failed to call this deletion variant from the same
BAM file using default recommended settings.
VarDict calls a new class of complex variants
Complex composite variants, wheremultiple InDels and/or
substitutions occur in close proximity, are also underrepre-
sented. Most variant callers we tested either call multiple
variants or give no call. Currently only FreeBayes has some
limited ability to call small complex variants with lengths
under 5 base pairs. VarDict, on the other hand, is able to call
much larger complex variants, involving insertion and/or
deletion of dozens of base pairs. Figure 3 illustrates a com-
plex composite variant, where an allele shows deletion of
29 bp followed by insertion of 13 bp (rs386762976, a re-
cent addition to dbSNP 138). This allele is in fact very com-
mon in the population. Analysis of hundreds of CCLE ex-
omes and TCGA germline exomes indicated it has preva-
lence over 40% in the population. The presence of a cluster
of dbSNP entries proximal to this variant is likely the re-
sult of erroneous calls from variant callers that were unable
to handle such complex variants, as evidenced by their ab-
sence in hundreds of germline exomes from TCGA that we
analyzed (data not shown).
Complex variant calling can have profound impact on
downstream clinical interpretation. It is known that in-
frame deletions in exon 19 in lung cancer patients activate
EGFR, and these patients would benefit from EGFR in-
hibiting drugs, such as gefitinib, erlotinib or AZD9291 (15–
17). Figure 4 shows such an example of EGFR exon 19 from
a lung cancer patient (15). Many variant callers return a se-
ries of individual out-of-frame EGFR InDel calls for these
events, suggesting the patient was ineligible for EGFR ther-
apy. VarDict is the only algorithm that correctly calls this
composite of variants as a single mutation, resulting in an
in-frame deletion event, likely to activate EGFR, render-
ing eligibility of EGFR inhibitor treatment. Furthermore,
VarDict rescues all aligning reads (including soft-clipped)
to sensitively quantify the variant AF.
To comprehensively evaluate VarDict’s complex variant
calling capability, we synthesized a dataset with 1,122 com-
plex variants within or close to every coding exon of com-
mon cancer genes (highlighted in bold in Supplementary
Table S2). Each complex variant combines a random dele-
tion of 1–50 bpwith a random insertion of 1–50 bp of differ-
ent sequences. Illumina HiSeq 2500 2 × 100 pair end reads
were simulated using ART (18) with 50× targeted depth
and aligned to hg19 using BWA MEM. VarDict, Pindel
(19) and Scalpel (20) were run against this synthetic dataset
and the results are shown in Supplementary Table S1. Var-
Dict was able to call 1113 (99%) of these events, 1073 of
which matched exactly with at nucleotide level, significantly
more than Pindel and Scalpel. Those that did not match
genotypes are due tomicrohomology with alternative align-
ments. This suggests VarDict is able to call a new class of
complex variants that would be otherwise missed.
VarDict is a structural variant caller
VarDict currently implements detection of three types
of SVs with no size limit: DEL; DUPs; and INVs. In
the TCGA-ICGC DREAM Mutation Calling challenge
dataset 4 (https://www.synapse.org/#!Synapse:syn312572/),
we demonstrated that VarDict has improved sensitivity over
Manta (21) and equivalent sensitivity to Lumpy (22) (Table
2). Of all methods tested, VarDict had the highest propor-
tion of exact matches for the breakpoints.
We also applied VarDict on NA12878 for which 2676
high quality DEL variants were recently reported (http:
//biorxiv.org/content/early/2015/05/22/019372), with sizes
ranging from 50 bp to 139 kb. VarDict was able to call 2407
(90%) of these deletions. We also evaluated VarDict’s AF
estimation for SVs. As NA12878 is a non-diseased sample
assumed to be diploid, we expected the AF of any event to
peak at 50 and 100%. As expected, the allele frequencies
of SVs called by VarDict do indeed show peaks at 50% and
100% (Figure 5). A seemingly smaller peak at 85%, however,
suggests room for further improvement in AF estimation.
VarDict performs paired analysis for both somatic and LOH
variants
VarDict paired analysis mode detects the emergence of new
mutations (typical of somaticmutation callers), and extends
to other variant classes such as LOH variants (where al-
lele specific loss results in a heterozygous variant becom-
ing either homozygous or lost completely), deleted variants,
as well as variants with significant shift in AF. This makes
VarDict more broadly applicable in cancer studies where it
is often necessary to go beyond typical tumor-normal so-
matic variant calling to the comparison of patient longitu-
dinal samples to monitor tumor evolution or the impact of
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Table 1. Comparison of different algorithms on a short 15-bp deletion variant calling
Method Deletion Depth Allele Freq (%)
Gapped reads only 336 488 69%
GATK (UnifiedGenotyper) 338 496 68%
GATK (HaplotypeCaller) 404 482 84%
FreeBayes 339 413 82%
VarDict 493 575 86%
The 15-bp deletion in EGFR exon 19 in lung cancer cell line PC-9 is shown in Figure 1. GATK UnifiedGenotyper does not recover soft-clipped reads,
and as expected, produces similar results when only gapped reads are considered. VarDict is able to recover more supporting soft-clipped reads from both
sides of deletion, while GATK’s HaplotypeCaller and FreeBayes only recover from one side, producing fewer deletion read counts and depth.
Figure 2. VarDict calls a large 124-bp deletion inNA12878. The deletion has clear support from both soft-clipped reads (colored reads) at both breakpoints
and the apparent drop of the coverage illustrated in the top track. The apparent consensus of the clipped sequences indicates the existence of an relatively
large InDel. Dark colored short reads are supplementary alignments from split reads, where individual reads are split into two segments that are aligned
at the edges flanking the deletion. The deletion variant was further supported by the existence of an entry in dbSNP (rs67488720). This deletion was
detected by VarDict, but not by GATK, VarScan, or FreeBayes.
therapeutic treatments. Using ICGC-TCGADREAMMu-
tation Calling challenge sets 3 and 4 we showed VarDict to
be a highly competitive variant caller with superior sensi-
tivity and specificity for InDel calling over popular variant
callers,MuTect, FreeBayes and VarScan (23), Figure 6. No-
tably MuTect only calls somatic SNVs.
VarDict calls more actionable mutations in lung cancer
TCGA analysis of cancer samples is considered the gold
standard in the field. To evaluate VarDict’s performance,
we downloaded exome and some whole genome data from
TCGA for 208 cancer genes of interests in 230 LUAD pa-
tient samples (Supplementary Table S2), processed using
VarDict and compared VarDict calls to the equivalent pub-
lished data (14). We demonstrated that, through sensitive
AF estimation and identification of missed complex vari-
ants and indels, VarDict calls known driver mutations in
the classical lung cancer oncogenes KRAS, EGFR, BRAF,
PIK3CA and MET in 16% more patients with mutations
(Figure 7, Supplementary Table S3). In addition, VarDict
reduces false negative calls (Figure 7) by filtering out vari-
ants of unknown significance with AF below 7.5%.
VarDict called known KRAS activating mutations (two
G12D, four G12V, three G12C, two G13D and one G12F)
in twelve additional patients, with AF ranging from 9–
43%. As expected, VarDict called more activating InDels
 at Periodicals D
ept on Septem
ber 7, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
e108 Nucleic Acids Research, 2016, Vol. 44, No. 11 PAGE 6 OF 11
Figure 3. VarDict calls a new class of complex variants. The clear drop out in coverage (top track) indicates a deletion from a complex variant example called
in NA12878 at chr12:51740388. Only the end portion of soft-clipped sequences, indicated by red arrows, can be aligned to the other side of the deletion
breakpoint, suggesting an additional proximal InDel may be present contributing to a complex composite variant. VarDict calls one single homozygous
complex variant, comprising of a 29-bp deletion followed by a 13-bp insertion (CTGGACCATATCCACTTACCATAAAGGAC >ACACCAGGAAGCG). This is
further supported by a recent entry in dbSNP (rs386762976). Many clustered dbSNP entries within the gap from dbSNP138 (bottom track), are likely
from mis-interpretation of mis-alignments.
Table 2. VarDict calls structural variants on the DREAMMutation Calling challenge set #4 for DEL, DUP and INV
Caller SV type Calls Exact hits Approximate hits True events
DEL 3536 426 898 1165
Lumpy DUP 1330 476 972 1142
INV 877 470 837 1029
DEL 695 479 686 1165
Manta DUP 875 539 840 1142
INV 1409 533 733 1029
DEL 1144 823a 877 1165
VarDict DUP 1139 883a 893 1142
INV 1277 616a 842 1029
We used keys provided by the DREAM challenge for exact hit (precise breakpoint) comparison. VarDict has similar sensitivity to Lumpy and higher than
Manta, although Manta has higher specificity for DEL and DUP. VarDict has much higher exact hit matches, demonstrating the preciseness of VarDict’s
algorithm.
aAll structural variants reported by VarDict have precise breakpoints, taking into account the microhomology around the breakpoint and perform 5′
adjustments according to HGVS recommendations.
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Figure 4. Complex variants can impact clinical interpretation. For this example of EGFR exon 19 deletion from a lung cancer patient (15), BWA produced
different alignments for reads with different lengths, some with two deletions and on insertion, while others are soft-clipped. The misalignment can be
incorrectly interpreted as insertion of a single base of C followed by an out of frame deletion. VarDict correctly calls a single complex mutation comprising
of a 26-bp deletion and a 5-bp insertion (TTAAGAGAAGCAACATCTCCGAAAGC>GCCAA), which explains all alignments, including soft-clipped reads. The
mutation will be thus annotated as an in-frame deletion of exon 19, which would be clinically actionable for EGFR inhibitor therapy.
Figure 5. The distribution of allele frequencies for structural variants es-
timated by VarDict. About 2407 high confidence large deletions from
NA12878 are called by VarDict. The x-axis shows the AF estimated by
VarDict while the y-axis shows the number of variants for a given AF. Two
expected peaks at 50 and 100% are visible, consistent with the germline
origin of the reference NA12878 sample.
in EGFR, such as three additional exon 19 mutations (one
deletion and two complex InDel composites) and two ad-
ditional exon 20 insertions (Supplementary Figure S1). The
supporting TCGAmanuscript (14) highlighted ten samples
showingMET exon 14 skipping as onemechanism forMET
activation. Interestingly, in cBio (24) three samples (TCGA-
Figure 6. Receiver operating characteristic (ROC) curve for comparison of
variant callers on DREAM synthetic dataset #4. The ROC curve is drawn
using quality scores for calls of somatic SNV and InDels provided by Free-
Bayes, VarScan,MuTect and VarDict.MuTect does not report quality and
depth was used in its place. There are total 21 913 of synthetic somatic
SNV and InDel mutations evaluated. VarDict outperforms other callers
with higher sensitivity and specificity. Variants were called and filtered us-
ing the default setting of each caller. It is worth noting that MuTect does
not call InDels.
44-6775, TCGA-55-6978 and TCGA-55-6986) are listed as
MET ‘exon 14 skip’ from analysis of RNA-Seq. Published
DNA-seq calls did not reveal anyMETmutations causative
for the exon 14 skip for these three samples. However, Var-
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Figure 7. The comparison of VarDict and Firehose calls for KRAS, EGFR, BRAF, PIK3CA and MET in 230 TCGA LUAD patients. Each column
represents a patient. Each gene has two rows, with the top showing calls from VarDict and the bottom showing calls from Firehose. Different colors
indicate different mutation types. Patients without matches in Firehose tracks indicate the mutations are only called by VarDict. As expected, all but one
KRASmutations aremissense, while EGFRhas known in-frame InDels. The patient with a truncatingmutation ofKRAS also contains an activatingG12V
mutation, suggesting the heterogeneous nature of the sample. Dark gray indicates mutations that are deemed as VUS (variant of unknown significance).
Trunc: Truncation; FS: Frameshift.
Dict called InDel and splice site mutations causative of
MET exon 14 skipping in two of the three samples (TCGA-
44-6775 and TCGA-55-6978). Furthermore, VarDict indi-
cated RNA-seq calls for the third sample (TCGA-55-6986)
may be false positive since no difference in exon 14 cov-
erage is evident (Supplementary Figure S2) and no muta-
tions were detected. More differences between VarDict and
Firehose/cBio variant calls were observed in tumor sup-
pressors, where InDel mutations are frequent. For example,
VarDict called an additional 11% (57 versus 46%) and 10%
(27 versus 17%) mutations in two common tumor suppres-
sors, TP53 and STK11 respectively (Supplementary Fig-
ure S3 and Table S3), many of which are truncating InDels
likely causing loss of function of the tumor suppressor. It is
notable that in all cases the newly detected mutations main-
tain mutually exclusivity across samples.
Collectively these data demonstrate the potential of Var-
Dict to improve sensitivity of variant calling over popu-
lar variant callers as used in the TCGA’s analysis pipeline.
Through VarDict re-calling of the TCGA data set we have
significantly altered the previously reported mutation land-
scape for LUAD, with potentially significant clinical impli-
cations where variant calls in these genes determine current
and emerging therapeutic choices.
VarDict performance is linear to depth
When sequencing plasma circulating free DNA (cfDNA)
where tumor content can be low, it is desirable to detect so-
maticmutation allele frequencies as low as 0.1%.As a result,
targeted gene panels enabling ultra-high depth (>5000×)
sequencing are increasingly being used in the clinical set-
ting. Computational run-time of most popular variant
callers scales exponentially with read depth, meaning these
algorithms are unable to handle ultra-high depth sequenc-
ing data on normal high-performance-computes without
downsampling (randomly removing reads) and compromis-
ing sensitivity of detection. VarDict’s unique algorithm de-
sign, which sequentially processes reads and performs lo-
cal realignment using aggregates, ensures performance lin-
ear with depth (Supplementary Figure S4). As a result, Var-
Dict has been successfully applied to longitudinally moni-
tor tumor variants in cfDNA in a recent non-small-cell lung
cancer clinical study of treatment with the EGFR inhibitor
Tagrisso AZD9291 (15). The study revealed a novel somatic
variant EGFR C797S responsible for emergence of resis-
tance to the drug. In this study, the median depth of EGFR
coverage was ∼30k, with peak depth >2M, otherwise im-
practical or not possible to process with other callers.
VarDict detects artifacts in PCR-based enrichment
PCR is often used to enrich targeted regions before library
construction, and is a known source of false positives in
NGS. Figure 8A demonstrates how VarDict is able to de-
tect variants that show amplicon bias when variants are cov-
ered by more than one PCR amplicon. In addition, VarDict
avoids false positives from primers that are mis-paired due
to high similarity (Figure 8B), deeming those reads to not
belong to any amplicon and thus not be used for variant
calling. Furthermore, when given the amplicon design with
PCR primer locations, VarDict will mask them in silico for
both depth calculation and variant calling, further improv-
ing sensitivity and specificity.
DISCUSSION
NGS is increasingly being applied in the clinic (25). As there
are many types of NGS, ranging from targeted PCR-based
sequencing toWGS, an accurate and versatile variant caller
is needed that can easily adapt to different situations. This
is especially important in cancer research where the com-
plex nature of the cancer genome coupled with variable tu-
mor content and sample quality (e.g. formalin fixation) de-
mands a variant caller that can meet these challenges (2).
We have demonstrated the versatility of VarDict over other
commonly used variant callers to better handle many of
these characteristics of cancer NGS data, proving it a valu-
able tool to facilitate cancer research.
Amongst the distinctive features of VarDict is its ability
to call complex variants, ranging from consecutive di-/tri-
nucleotide variants, to much more complex composites of
insertions and deletions. In breast and ovarian cancer pa-
tients di-nucleotide mutations have been found to cause a
stop codon and truncation of the tumor suppressor gene
BRCA1 actionable for PARP inhibitor therapy (26) but of-
ten misclassified as two inactionable missense mutations. In
>1% of all LUAD patients two neighboring frameshift In-
Dels are found on the same allele of EGFR exon 19 that
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Figure 8. Common artifacts from PCR based target enrichment. (A) Amplicon biased variants. Four overlapping PCR amplicons were designed against
EGFR exon 12. The red arrow highlights a variant with AF of 24% and predicted to be C499Y, which has an entry is COSMIC. However, it is detectable
only in amplicon 3 and will be flagged by VarDict and filtered. (B) Mis-paired primers amplified a region with EGFR exon 20. The read pairs highlighted
by a red rectangle can not be mapped to any of the amplicons (5-7) below. The two mismatches at the left are actually a primer from ERBB2, which has
high sequence similarity to EGFR resulting in primer mis-pairing. VarDict will filter out all those reads and thus no variant will be called from those
mismatches in the mis-paired primer. Numbers (1-7) at the bottom indicate PCR amplicons, with thick middle portion for inserts and thin edges for PCR
primers.
are in fact a single complex composite variant producing an
in-frame deletion that activates the EGFR protein and ren-
ders patients eligible for EGFR inhibitor therapy. In fact, in
TCGA LUAD, 8 out 32 (25%) patients with exon 19 dele-
tion mutations are complex variants (Supplementary Table
S3). Alongside this significant clinical relevance, an inability
to call complex variants also has a considerable impact on
annotation presented in current reference databases includ-
ing dbSNP and COSMIC (5). We often observe proximal
clusters of entries in dbSNP originating from the same sam-
ple, all of which in fact contribute to a single complex vari-
ant call at the same position by VarDict (Figure 3). Analysis
of large sample cohorts often failed to find the existence of
most of these entries, further supporting them to be erro-
neous calls created either due to the inability of Sanger se-
quencing for phasing, or the inability of other variant callers
to call complex variants.
NGS is now being adopted to address more complex
problems such as disseminating the genetic sub-clonality
of heterogeneous tumor samples. Furthermore these ques-
tions are being asked in increasingly difficult samples such
as FFPE and cfDNA from cancer patients. Researchers and
clinicians are therefore increasingly interested in sensitive
detection of low AF mutations. To achieve this, it is neces-
sary to sequence at coverage depth>1000×, however, many
popular variant callers do not scale well at such coverage
depth. VarDict’s ability to scale linearly to depth makes
it suitable for ultra-deep targeted sequencing, as demon-
strated in the discovery of the EGFR C797S mutation as
a resistant mechanism to AZD9291 in NSCLC harboring
EGFR T790M mutation (15). In fact, in that study, Var-
Dict was the only variant caller that successfully completed
in time (mostly overnight) with the desired sensitivity, while
other callers attempted either failed to run or were not sen-
sitive enough to detect low AF EGFR mutations resistant
to AZD9291 (15).
As many targeted cancer drugs approved or in develop-
ment use mutations in a handful of genes as patient selec-
tion biomarkers, PCR is often the technology of choice to
amplify those genes before submitting them to sequencing.
However, it is known that PCR can produce artifacts and if
not dealt with carefully can lead to false positive/negative
variant calls in downstream analysis, impacting clinical de-
cisions. VarDict’s abilities to detect PCR artifacts, such as
amplicon bias andmis-paired primers, together with the lin-
ear scalability to depth, make it desirable in such studies to
reduce both false positives and false negatives.
Somatic mutations are of high interest in cancer, as well
as mutations that change allele frequencies significantly af-
ter treatment or during tumor evolution over time. Var-
Dict is also able to perform paired analyses to identify such
variant changes. VarDict was demonstrated to be a very
effective somatic mutation calling for both SNV and In-
Dels (27). In addition to somatic mutations, VarDict will
identify germline, LOH and/or deleted variants, making it
more suitable for comparison of paired longitudinal sam-
ples, for example pre- and post-treatment comparisons rou-
tinely investigated to understand drug resistance mecha-
nisms in cancer research.
We further demonstrated the accuracy of VarDict calls
through re-analysis of exome sequencing of 230 TCGA
LUAD patient samples and comparison to data in Fire-
hose and cBio, a commonly accepted gold standard in the
field. To our surprise, VarDict calls 16% more patients
with known activating mutations in well known lung can-
cer driver oncogenes, KRAS, EGFR, BRAF, PIK3CA and
MET. In addition a number of somatic mutations with
unknown functional significance in these genes were also
called by VarDict, potentially revealing actionable muta-
tions in even more patients missed by the gold standard
analyses. This clearly has big impact in clinics where NGS
is used to identify mutations for patient enrolment. For ex-
ample, failure to detect a complex EGFR exon 19 dele-
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tion might prevent a lung cancer patient receiving clini-
cally proven beneficial therapy, such as gefitinib or erlotinib
(16,17). On the other hand, failure to detect a KRASmuta-
tion might direct a colon cancer patient into EGFR thera-
pies, such as cetuximab or panitumumab, which has been
proven to not be beneficial (28,29). The effect might be
even larger for tumor suppressors, such as BRCA1, BRCA2,
TP53, RB1 and STK11, where InDel mutations are a com-
mon mechanism of loss of function but are poorly detected
by other callers.
Many known cancer driver fusions, such as EML4-ALK
(30) in lung cancer, are the result of SVs due to large re-
arrangements and are clinically actionable. Oncogenes in-
volved in fusions, such as ROS1 in lung cancer, often have
different fusion partners in different patient subsets (31),
which prevents design of a universal assay to detect all po-
tential fusions. Since NGS is unbiased to any particular fu-
sion partnership it is increasingly being used to detect fu-
sions. Internal gene rearrangements involving one or more
exons are also a common mechanism by which tumor sup-
pressors such as BRCA1 and BRCA2 to lose functions (32),
and are eligible for targeted therapies (26). Identification of
fusions and rearrangements typically involves a custom step
of analysis requiring different software. This will be simpli-
fied by the ability to accurately call multiple types of SVs in
NGS in a single step with VarDict. VarDict can also esti-
mate allele frequencies for SVs, further facilitating the in-
terpretation of their clinical relevance. However, in order
to increase the specificity, VarDict currently heavily relies
on split reads, coupled with discordant mate pairs to detect
SVs at precise breakpoints. This does limit its sensitivity in
lower coverage WGS where split reads are less likely to be
sequenced and aligned. Further work is needed to improve
its sensitivity in such scenario while maintaining specificity.
These properties, and the value to detect otherwise
missed variants in cancer samples demonstrated in
this manuscript, highlight VarDict as a unique variant
caller of high value in cancer translational research.
The algorithm is open source and freely available for
public use. As the only published variant caller scal-
able to ultra-deep sequencing and capable of calling
all variant types, including complex variants and SVs,
we believe VarDict fills a gap in NGS analysis crit-
ical to interpretation of tumor genome complexity
to advance our understanding and treatment of cancer.
AVAILABILITY
VarDict is implemented in Perl and is publicly available in
GitHub (https://github.com/AstraZeneca-NGS/VarDict).
A Java re-implementation of VarDict with improved
performance is also publicly available in GitHub
(https://github.com/AstraZeneca-NGS/VarDictJava),
but currently without the SV calling capability.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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